Malignant lymphoma
Conditions
Interventions
None listed
Sponsors
Agency for Medical Research and Development; Program for an Integrated Database of Clinical and Genomic Information; Horibe research team.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All items listed below are required. 1) Diagnosed as diffuse large B-cell lymphoma (DLBCL) in WHO classification (2016). 2) Twenty years old or higher age. 3) Tumor or non-tumor tissues are available for genome analyses. Tumor tissue sample: a) and b) a) biopsy sample at diagnosis (frozen tissues, cell suspension, or genome DNA) b) Formalin fixed parafin embedded (FFPE) tissue section samples for histological analyses. Non-tumor tissue samples: a) or b) a) peripheral blood sample at diagnosis b) peripheral blood sample at entry 4) Patients who filled out the informed consent forms.
Exclusion criteria
Exclusion criteria: 1) Patients enrolled in another critical trials for treatment. 2) Patients who can not obtain enough amount of DNA samples for genome analyses. 3) A subject considered as an inappropriate participant for the current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of potentially actionable findings(PAF), used as a feedback to the attending physician | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Percentage of clinically impactful findings (CIF) identified 2) Average number of days required to return analysis results to physicians in charge 3) Percentage of cases in which genome analysis is not possible and the causes 4) Percentage of cases with identified germline mutations eligible for return | — |
Countries
Japan
Contacts
Public ContactAkinaol Okamoto
Fujita Health University School of Medicine Department of Hematology
Outcome results
None listed